There is clear evidence that angiotensin-converting enzyme (ACE)-inhibitors and angiotensin-receptor blockers (ARBs) appear to be more effective than atenolol in terms of microvascular protection also in patients with diabetes mellitus [85,86,87]. This evidence concerns the gene ACE and diabetes mellitus.